166 related articles for article (PubMed ID: 19124661)
1. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
Prakash V; Lewis JS; Herrera ML; Wickes BL; Jorgensen JH
Antimicrob Agents Chemother; 2009 Mar; 53(3):1278-80. PubMed ID: 19124661
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
Alhambra A; Cuadros JA; Cacho J; Gómez-Garcés JL; Alós JI
J Antimicrob Chemother; 2004 Jun; 53(6):1090-4. PubMed ID: 15117925
[TBL] [Abstract][Full Text] [Related]
3. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
[TBL] [Abstract][Full Text] [Related]
4. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
5. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
[TBL] [Abstract][Full Text] [Related]
6. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
7. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
[TBL] [Abstract][Full Text] [Related]
8. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
[No Abstract] [Full Text] [Related]
9. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
Auer S; Wojna A; Hell M
Antimicrob Agents Chemother; 2010 Sep; 54(9):4006-8. PubMed ID: 20585127
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum β-lactamases and the role of fosfomycin.
Kresken M; Pfeifer Y; Hafner D; Wresch R; Körber-Irrgang B;
Int J Antimicrob Agents; 2014 Oct; 44(4):295-300. PubMed ID: 25223936
[TBL] [Abstract][Full Text] [Related]
12. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
14. Molecular Characterization of Extended-Spectrum β-Lactamase
Shash RY; Elshimy AA; Soliman MY; Mosharafa AA
Am J Trop Med Hyg; 2019 Mar; 100(3):522-528. PubMed ID: 30594263
[TBL] [Abstract][Full Text] [Related]
15. Characterization of extended-spectrum beta-lactamases produced by Escherichia coli isolated from hospitalized and nonhospitalized patients: emergence of CTX-M-15-producing strains causing urinary tract infections.
Smet A; Martel A; Persoons D; Dewulf J; Heyndrickx M; Claeys G; Lontie M; Van Meensel B; Herman L; Haesebrouck F; Butaye P
Microb Drug Resist; 2010 Jun; 16(2):129-34. PubMed ID: 20370505
[TBL] [Abstract][Full Text] [Related]
16. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.
Ellington MJ; Livermore DM; Pitt TL; Hall LM; Woodford N
J Antimicrob Chemother; 2006 Oct; 58(4):848-52. PubMed ID: 16891630
[TBL] [Abstract][Full Text] [Related]
17. Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen.
Lee CH; Su LH; Lin WC; Tang YF; Liu JW
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e183-6. PubMed ID: 19800278
[TBL] [Abstract][Full Text] [Related]
18. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
19. Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients.
Brigante G; Luzzaro F; Perilli M; Lombardi G; Colì A; Rossolini GM; Amicosante G; Toniolo A
Int J Antimicrob Agents; 2005 Feb; 25(2):157-62. PubMed ID: 15664486
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
